Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 28 Nov 2022 for Lipocine Inc., €9,972. Read the official filing
Filing timeline
BuySaleSpyros Papapetropoulos
Insider track record
Disclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-20.1%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Spyros Papapetropoulos: trading record in brief
Filings by Spyros Papapetropoulos span 2 companies, the busiest being Vigil Neuroscience, Inc. and Lipocine Inc. We count 3 filings; the first trade dates from 3 May 2022 and the latest from 22 November 2022.
Every open-market trade on record is a purchase: 2 purchases worth €23k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 option exercise.
The newest entry dates from 28 November 2022: an open-market purchase of €9,972, in Lipocine Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Spyros Papapetropoulos
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
21,739 shares@ US$0.47100.0% of flowCommon stockSEC:0001493152-22-033841:0
Canonical exit: 20 Feb 2023 (T+90)
300 shares@ US$1.894.1% of flowCommon StockSEC:0000899243-22-036831:0
4,000 shares@ US$3.397895.9% of flowCommon StockSEC:0000899243-22-016530:0
Canonical exit: 1 Aug 2022 (T+90)
3 of 3 declarations
